Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
TL-895 blocks the action of an enzyme called Bruton's tyrosine kinase (BTK). Tyrosine kinases are involved in many cell functions, including signaling, growth, and division. The activation of BTK in mast cells may trigger ISM symptoms. TL-895 is taken orally (by mouth).
Researchers want to find the best dose of RYZ801 to give with RYZ811 in people with inoperable liver cancer. Inoperable means the cancer cannot be taken out with surgery. The people in this study have hepatocellular carcinoma (HCC) that makes high levels of a liver protein called GPC3.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Anaplastic large cell lymphoma (ALCL) is a type of T-cell cancer. This cancer has a fusion (change) in the ALK gene. The fusion gene makes a protein that promotes cancer growth and survival. This type of cancer is called ALK-positive ALCL.
Researchers want to find the best dose of TTI-101 that can be used safely alone and with other drugs for cancer. The people in this study have hepatocellular carcinoma (liver cancer) that has metastasized (spread) or is inoperable (surgically unremovable).
Researchers want to find the best dose of ABBV-453 to treat multiple myeloma. The people in this study have multiple myeloma that may have a genetic change and make too much of the BCL2 protein. In addition, their cancer has not responded to treatment or has returned after treatment.
Researchers want to find the best doses of RMC-6291 and RMC-6236 when given together to treat lung cancer and other types of cancer that have KRAS G12C mutations. The people in this study have advanced non-small cell lung cancer (NSCLC) or colorectal cancer with a gene mutation (change) called KRAS G12C.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to see how well selinexor works in people with Wilms' tumor and other solid tumors. The people in this study are children and adults with tumors that depend on a protein called XPO1. XPO1 helps cancer cells grow by getting rid of proteins that can cause those cells to die (tumor suppressor proteins).
